Table 2

Clinical features and genetic findings for the patients with t-MN and relapsed APL

Disease type/patient no.At APL diagnosis (A)
Interval from A to B, yAt relapse or t-MN (B)
Survival from B, y
Age, y/sexWBCs, ×109/LPlatelets, ×109/LFAB classificationKaryotype*PML-RARAClass I mutations†FAB classificationKaryotype*PML-RARAOther class II abnormalities†Class I mutations†
t-MN with progression to AML               
    10‡ 38/F 1.10 17 M3 46,XX[20] + − 5.1 RAEBt 45,XX,-7[19]/46,idem,+21[1] − RUNX1 D171N NRAS G12V 0.8 
    18 38/M 1.10 43 M3 46,XY,t(15;17)(q22;q21)[17]/46,XY[3] + − 4.0 RAEB 45,XY,-7[3]/46,XY[17] − RUNX1 D171G − 2.0 
    19 35/M 42.60 10 M3 46,XY,t(15;17)(q22;q21)[20] + − 2.4 RAEBt 46,XY,t(7;15)(q11;q11),der(12)t(12;17)(p11;q21), t(16;21)(q24;q22),add(17)(q11),add(19)(p13), del(21)(q21)[3]/46,idem,der(18)t(15;18)(q11;p11) [6]/46,XY[11] − RUNX1-MTG16 − 1.9 
    22 48/M 1.80 110 M3 46,XY,t(15;17)(q22;q21)[18]/46,XY[2] + − 9.7 M0 46,XY,add(13)(q32)[19]/46,XY[1] − − − 0.8 
    48 57/F 4.10 16 M3 46,XX,t(15;17)(q22;q21)[19]/46,XX[1] + − 1.4 M1 46,XX,t(6;11)(q21;q23)[16]/46,XX[4] − MLL-FOXO3 − > 8.7 
    79 62/M 2.20 54 M3 46,XY,t(15;17)(q22;q21)[19]/46,XY[1] + − 2.6 RAEB 46,XY,add(2)(p23),inv(5)(p11q13), add(11)(q23)[14]/46,idem, inv(2)(p23q11)[4]/47,idem,+13[2] − RUNX1 S295fsX571 − 1.3 
    83 42/M 1.20 144 M3 46,XY,t(15;17)(q22;q21)[17]/46,XY[3] + − 2.5 RAEB 45,XY,-7[19]/46,XY[1] − RUNX1 G172W − 1.7 
    108 18/M 14.40 36 M3 46,XY,t(15;17)(q22;q21)[20] + − 1.0 M4 46,XY,t(11;16)(q23;p13.3)[6] /46,XY[14] − MLL-CBP FLT3ITD 2.6 
    109 65/M 1.68 41 M3 46,XY,t(15;17)(q22;q21)[20] + − 1.3 RAEB 46,XY[20] − CEBPA Q305P − 1.7 
t-MN without progression to AML (t-MDS-RCMD)               
    7 54/F 4.50 6 M3 46,XX,t(15;17)(q22;q21)[20] + − 1.6 RA 46,XX,del(20)(q11)[15]/46,XX[5] − − − > 13.4 
    49 67/M 1.62 42 M3 45,X,-Y,t(15;17)(q22;q21), del(14)(q13q22)[18]/46,XY[2] + − 3.0 RA 46,XY,del(20)(q1?)[3]/46,XY[17] − − − > 6.9 
Relapse               
    8 54/M 1.30 258 M3 46,XY,t(15;17)(q22;q31)[20] + − 3.4 M3 46,XY,add(9)(q22),add(13)(p11), t(15;17)(q22;q21)[3]/46,XY[17] + − − > 11.4 
    12 32/M 12.67 7 M3 46,XY,t(9;X)(p24;q22), t(15;17)(q22;q21)[20] + − 0.6 M3 ND + − FLT3ITD 2.4§ 
    13 38/M 95.70 35 M3 47,XY,+mar1[17]/46,XY[3] + − 10.1 M3 48,XY,+mar1x2[13]/46,XY[7] + − − > 3.6 
    17 53/F 4.80 52 M3 46,XX[20] + − 2.0 M3 46,XX[20] + − − > 11.1 
    25 58/F 148.60 31 M3v 46,XX[20] + FLT3ITD 1.5 M3v 46,XX[20] + − FLT3ITD 0.8 
    38 64/F 15.70 27 M3 46,XX,t(15;17)(q22;q21)[20] + FLT3ITD 1.0 M3 46,XX,t(15;17)(q22;q21)[20] + − FLT3ITD 1.7 
    78 39/M 7.03 13 M3 48,XY,+8,+8,t(15;17)(q22;q21)[10]/49,idem,+21[9]/46,XY[1] + − 1.1 M3 ND + − − 0.9‖ 
    85 19/M 1.10 152 M3v 49,XY,t(15;17)(q22;q21),+mar1, +mar2, +mar3[16]/46,XY[4] + − 2.5 M3v 49,XY,t(15;17)(q22;q21),+mar1, +mar2, +mar3[15]/46,XY[5] + − − > 4.2 
    88 46/M 4.60 47 M3 46,XY[20] + FLT3ITD 1.8 M3 46,XY[20] + − FLT3ITD > 4.8 
    95 55/M 44.80 21 M3v 46,XY,t(15;17)(q22;q31)[20] + − 1.8 M3v 46,XY,t(15;17)(q22;q21)[17] /46,XY[3] + − − > 4.0 
Disease type/patient no.At APL diagnosis (A)
Interval from A to B, yAt relapse or t-MN (B)
Survival from B, y
Age, y/sexWBCs, ×109/LPlatelets, ×109/LFAB classificationKaryotype*PML-RARAClass I mutations†FAB classificationKaryotype*PML-RARAOther class II abnormalities†Class I mutations†
t-MN with progression to AML               
    10‡ 38/F 1.10 17 M3 46,XX[20] + − 5.1 RAEBt 45,XX,-7[19]/46,idem,+21[1] − RUNX1 D171N NRAS G12V 0.8 
    18 38/M 1.10 43 M3 46,XY,t(15;17)(q22;q21)[17]/46,XY[3] + − 4.0 RAEB 45,XY,-7[3]/46,XY[17] − RUNX1 D171G − 2.0 
    19 35/M 42.60 10 M3 46,XY,t(15;17)(q22;q21)[20] + − 2.4 RAEBt 46,XY,t(7;15)(q11;q11),der(12)t(12;17)(p11;q21), t(16;21)(q24;q22),add(17)(q11),add(19)(p13), del(21)(q21)[3]/46,idem,der(18)t(15;18)(q11;p11) [6]/46,XY[11] − RUNX1-MTG16 − 1.9 
    22 48/M 1.80 110 M3 46,XY,t(15;17)(q22;q21)[18]/46,XY[2] + − 9.7 M0 46,XY,add(13)(q32)[19]/46,XY[1] − − − 0.8 
    48 57/F 4.10 16 M3 46,XX,t(15;17)(q22;q21)[19]/46,XX[1] + − 1.4 M1 46,XX,t(6;11)(q21;q23)[16]/46,XX[4] − MLL-FOXO3 − > 8.7 
    79 62/M 2.20 54 M3 46,XY,t(15;17)(q22;q21)[19]/46,XY[1] + − 2.6 RAEB 46,XY,add(2)(p23),inv(5)(p11q13), add(11)(q23)[14]/46,idem, inv(2)(p23q11)[4]/47,idem,+13[2] − RUNX1 S295fsX571 − 1.3 
    83 42/M 1.20 144 M3 46,XY,t(15;17)(q22;q21)[17]/46,XY[3] + − 2.5 RAEB 45,XY,-7[19]/46,XY[1] − RUNX1 G172W − 1.7 
    108 18/M 14.40 36 M3 46,XY,t(15;17)(q22;q21)[20] + − 1.0 M4 46,XY,t(11;16)(q23;p13.3)[6] /46,XY[14] − MLL-CBP FLT3ITD 2.6 
    109 65/M 1.68 41 M3 46,XY,t(15;17)(q22;q21)[20] + − 1.3 RAEB 46,XY[20] − CEBPA Q305P − 1.7 
t-MN without progression to AML (t-MDS-RCMD)               
    7 54/F 4.50 6 M3 46,XX,t(15;17)(q22;q21)[20] + − 1.6 RA 46,XX,del(20)(q11)[15]/46,XX[5] − − − > 13.4 
    49 67/M 1.62 42 M3 45,X,-Y,t(15;17)(q22;q21), del(14)(q13q22)[18]/46,XY[2] + − 3.0 RA 46,XY,del(20)(q1?)[3]/46,XY[17] − − − > 6.9 
Relapse               
    8 54/M 1.30 258 M3 46,XY,t(15;17)(q22;q31)[20] + − 3.4 M3 46,XY,add(9)(q22),add(13)(p11), t(15;17)(q22;q21)[3]/46,XY[17] + − − > 11.4 
    12 32/M 12.67 7 M3 46,XY,t(9;X)(p24;q22), t(15;17)(q22;q21)[20] + − 0.6 M3 ND + − FLT3ITD 2.4§ 
    13 38/M 95.70 35 M3 47,XY,+mar1[17]/46,XY[3] + − 10.1 M3 48,XY,+mar1x2[13]/46,XY[7] + − − > 3.6 
    17 53/F 4.80 52 M3 46,XX[20] + − 2.0 M3 46,XX[20] + − − > 11.1 
    25 58/F 148.60 31 M3v 46,XX[20] + FLT3ITD 1.5 M3v 46,XX[20] + − FLT3ITD 0.8 
    38 64/F 15.70 27 M3 46,XX,t(15;17)(q22;q21)[20] + FLT3ITD 1.0 M3 46,XX,t(15;17)(q22;q21)[20] + − FLT3ITD 1.7 
    78 39/M 7.03 13 M3 48,XY,+8,+8,t(15;17)(q22;q21)[10]/49,idem,+21[9]/46,XY[1] + − 1.1 M3 ND + − − 0.9‖ 
    85 19/M 1.10 152 M3v 49,XY,t(15;17)(q22;q21),+mar1, +mar2, +mar3[16]/46,XY[4] + − 2.5 M3v 49,XY,t(15;17)(q22;q21),+mar1, +mar2, +mar3[15]/46,XY[5] + − − > 4.2 
    88 46/M 4.60 47 M3 46,XY[20] + FLT3ITD 1.8 M3 46,XY[20] + − FLT3ITD > 4.8 
    95 55/M 44.80 21 M3v 46,XY,t(15;17)(q22;q31)[20] + − 1.8 M3v 46,XY,t(15;17)(q22;q21)[17] /46,XY[3] + − − > 4.0 

M3v indicates M3 variant; ND, not done; +, positive; and −, negative.

*

Numbers in square brackets are cell numbers.

†

Class I mutations include the FLT3 and NRAS mutations, and other class II abnormalities include the chimeric proteins and the RUNX1 and CEBPA mutations.

‡

This patient was reported previously6 (case 8).

§

This patient died from an accident during the third CR.

‖

This patient refused reinduction therapy and died of cerebral bleeding.

View Large